Prospective study of predictor for efficiency of treatment with Nintedanib for idiopathic pulmonary fibrosis
Phase of Trial: Phase IV
Latest Information Update: 11 May 2018
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Biomarker; Therapeutic Use
- 05 May 2018 Status changed from not yet recruiting to recruiting.
- 27 Feb 2018 Planned End Date changed from 31 Mar 2019 to 30 Sep 2019.
- 08 Oct 2017 Planned End Date changed from 30 Sep 2018 to 31 Mar 2019.